首页> 外文期刊>American Journal of Neuroradiology >Prognostic Value of MR and Magnetization Transfer Imaging Findings in Patients withClinically Isolated Syndromes Suggestive ofMultiple Sclerosis at Presentation
【24h】

Prognostic Value of MR and Magnetization Transfer Imaging Findings in Patients withClinically Isolated Syndromes Suggestive ofMultiple Sclerosis at Presentation

机译:MR和磁化转移影像学检查对提示多发性硬化的临床孤立综合征患者的预后价值

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND AND PURPOSE: The extent of abnormalities on T2-weighted MR images of the brain of patients with clinically isolated syndromes (CIS) suggestive of multiple sclerosis (MS) at presentation is associated with an increased risk of developing clinically definite MS (CDMS). We evaluated whether subtle changes outside T2-visible lesions are present in the brain of these patients and whether their extent increases the risk of subsequent development of CDMS. METHODS: Dual-echo, T1-weighted, and magnetization transfer (MT) images of the brain were obtained from 24 patients with CIS at presentation. These patients were followed up for a mean period of 33 months (range, 25–42 months). Twenty age- and sex-matched healthy volunteers served as control subjects. To create MT histograms of the normal-appearing brain tissue (NABT), macroscopic lesions were segmented from dual-echo images, were superimposed automatically, and were nulled out from the coregistered and scalp-stripped MT ratio (MTR) maps. The following MTR histogram-derived measures were considered: average MTR, MTR25, MTR50, MTR75, peak height, and peak position. T2 and T1 lesion loads, average lesion MTR, and brain volume were also measured. RESULTS: Patients with CIS had lower average NABT-MTR (P sup> .0001) and peak position (P = .002) than did control volunteers, but patient brain size was similar to that of volunteers. At follow-up, 10 (41%) patients developed CDMS. Patients who developed CDMS during the follow-up period had higher T2 lesion volume (P = .003) and lower average NABT-MTR (P = .005) and peak position (P = .006) than did those who did not develop CDMS. T2 lesion volume (odd ratio, 3.54; P = .0005) and average NABT-MTR (odd ratio, 0.81; P = .01) were independent predictors of the subsequent development of CDMS. CONCLUSION: Subtle changes occur outside lesions visible on conventional MR images among patients with CIS suggestive of MS at presentation. The greater the extent of such abnormalities is, the higher is the risk of subsequent development of CDMS.
机译:背景与目的:临床表现为多发性硬化症(MS)的临床分离的 综合征(CIS)患者的脑部T2加权 MR图像异常程度< sup> 与发生临床上 定型MS(CDMS)的风险增加相关。我们评估了这些患者 的大脑中是否存在 T2可见病变以外的细微变化,以及它们的程度是否增加了随后发展为 的风险CDMS。 方法:从24例 CIS患者中获取了双回波,T1加权和磁化转移的大脑图像。在演示中。对这些患者进行了平均为期33个月(25-42个月)的随访。二十名年龄 和性别匹配的健康志愿者作为对照组。 要创建正常外观的脑组织的MT直方图,从双回波图像中分割出宏观病变,自动叠加 ,并从 共同登记和头皮剥离的MT比(MTR)图中将其消除。考虑以下 MTR直方图度量:平均MTR, MTR 25 ,MTR 50 ,MTR 75 ,峰高和峰位置。还测量了T2和 T1病变负荷,平均病变MTR和脑容量。 结果:CIS患者的平均NABT-MTR较低( P .0001)和峰值位置(P = .002)比对照组自愿者高, 但患者的大脑大小与自愿者相似。在 随访中,有10名(41%)患者发展了CDMS。在随访期间发展为 CDMS的患者具有更高的T2病变体积 (P = .003)和较低的平均NABT-MTR(P = .005)和峰值位置 (P = .006)比那些没有开发CDMS的人要好。 T2病变 体积(比率为3.54; P = .0005)和平均NABT-MTR(比率为0.81; P = .01)是随后发生的独立预测因子结论:CIS患者常规MR图像可见的病灶外细微变化发生在提示ss的CIS患者中,提示 演讲中的女士。 的异常程度越大,随后发生CDMS的风险就越高。

著录项

  • 来源
    《American Journal of Neuroradiology》 |2000年第6期|1034-1038|共5页
  • 作者单位

    From the Neuroimaging Research Unit (G.I., C.T., M.R., M.P.S., M.F.) and the Unit of Clinical Trials (G.C.), Department of Neuroscience Scientific Institute Ospedale San Raffaele, Milan, and the Unit of Clinical Epidemiology and Trials (M.P.S.), Institute for Cancer Research, Genoa, Italy.;

    From the Neuroimaging Research Unit (G.I., C.T., M.R., M.P.S., M.F.) and the Unit of Clinical Trials (G.C.), Department of Neuroscience Scientific Institute Ospedale San Raffaele, Milan, and the Unit of Clinical Epidemiology and Trials (M.P.S.), Institute for Cancer Research, Genoa, Italy.;

    From the Neuroimaging Research Unit (G.I., C.T., M.R., M.P.S., M.F.) and the Unit of Clinical Trials (G.C.), Department of Neuroscience Scientific Institute Ospedale San Raffaele, Milan, and the Unit of Clinical Epidemiology and Trials (M.P.S.), Institute for Cancer Research, Genoa, Italy.;

    From the Neuroimaging Research Unit (G.I., C.T., M.R., M.P.S., M.F.) and the Unit of Clinical Trials (G.C.), Department of Neuroscience Scientific Institute Ospedale San Raffaele, Milan, and the Unit of Clinical Epidemiology and Trials (M.P.S.), Institute for Cancer Research, Genoa, Italy.;

    From the Neuroimaging Research Unit (G.I., C.T., M.R., M.P.S., M.F.) and the Unit of Clinical Trials (G.C.), Department of Neuroscience Scientific Institute Ospedale San Raffaele, Milan, and the Unit of Clinical Epidemiology and Trials (M.P.S.), Institute for Cancer Research, Genoa, Italy.;

    From the Neuroimaging Research Unit (G.I., C.T., M.R., M.P.S., M.F.) and the Unit of Clinical Trials (G.C.), Department of Neuroscience Scientific Institute Ospedale San Raffaele, Milan, and the Unit of Clinical Epidemiology and Trials (M.P.S.), Institute for Cancer Research, Genoa, Italy.;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号